Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

January 18, 2002




The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Introduction Pravastatin-Aspiring, Fred T Fiedorek, MD, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute, Bristol-Myers Squibb  ppt  htm

Pravastatin-Aspirin Combination, Rene Belder, MD, Clinical Design and Evaluation, Metabolics Pharmaceutical Research Institute  ppt   htm

Efficacy of the Combination:  Meta-Analyses, Donald A Berry, PhD, Frank T. McGraw Memorial Chair of Cancer Research, University of Texas, MD Anderson Cancer Center   ppt   htm

Pravastatin-Aspirin Combination: The Medical Need, Thomas A Pearson, MD, PhD, Albert D Kaiser Professor of Community & Preventive Medicine, University of Rochester, School of Medicine  ppt  htm